# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0000950170-25-088700
**Filing Date:** 2025-6
**Character Count:** 43693
**Document Hash:** 5f2189b868148c75cfd940d58f44f2a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-088700.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0000950170-25-088700

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 80

**CONFORMED PERIOD OF REPORT**: 20250621

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Perspective Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411458152
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 251062908

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-676-0900

**MAIL ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Isoray, Inc.
- **DATE OF NAME CHANGE:** 20181231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 21, 2025<br>

------

Perspective Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-33407 | 41-1458152 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| c/o Perspective Therapeutics, Inc.<br>2401 Elliott Avenue<br>Suite 320 |  |  |
| Seattle**,** Washington |  | 98121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (206) 676-0900<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | CATX | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## **Item 8.01 Other Events.** 
On June 21, 2025, Perspective Therapeutics, Inc. (the "Company") issued a press release announcing that alignment was reached with the U.S. Food and Drug Administration to open the third dosing cohort of its ongoing Phase 1/2a clinical trial for [<sup>212</sup>Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Additionally, on June 21, 2025, the Company issued a press release and posted to its website a presentation regarding a dosimetry sub-study using [<sup>202</sup>Pb]VMT-α-NET as an imaging agent in the Company's ongoing Phase 1/2a clinical trial of [<sup>212</sup>Pb]VMT-α-NET that was accepted for presentation at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting, which is taking place from June 21-24, 2025 in New Orleans, Louisiana. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01. A copy of the presentation is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

On June 23, 2025, the Company updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.4 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

## **Item 9.01 Financial Statements and Exhibits.** 
(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [<u>Press release #1 issued by Perspective Therapeutics, Inc., dated June 21, 2025</u>](catx-ex99_1.htm). |
| 99.2 | [<u>Press release #2 issued by Perspective Therapeutics, Inc., dated June 21, 2025</u>](catx-ex99_2.htm). |
| 99.3 | [<u>Presentation regarding data presented at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting</u>](catx-ex99_3.htm). |
| 99.4 | [<u>Corporate Presentation</u>](catx-ex99_4.htm). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PERSPECTIVE THERAPEUTICS, INC.** |
| Date: | June 23, 2025 | By:  | /s/ Johan (Thijs) Spoor |
|  |  |  | Johan (Thijs) Spoor<br>Chief Executive Officer |

---

------

## Exhibit 99.1

![img236230851_0.jpg](img236230851_0.jpg)

**Perspective Therapeutics Commences Recruitment for [**<sup>212</sup>**Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*[*<sup>212</sup>*Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [*<sup>212</sup>*Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment*

SEATTLE – June 21, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [<sup>212</sup>Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT).

"We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs."

------

Patients in Cohort 3 will receive up to four fixed administered doses of [<sup>212</sup>Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3.

Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course.

**About [**<sup>212</sup>**Pb]VMT-α-NET**

Perspective designed [<sup>212</sup>Pb]VMT-α-NET to target and deliver <sup>212</sup>Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [<sup>212</sup>Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol.

**About Perspective Therapeutics, Inc.**

Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope <sup>212</sup>Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary <sup>212</sup>Pb generator, to deliver patient-ready products for clinical trials and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

------

**Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope <sup>212</sup>Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary <sup>212</sup>Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.

These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**Media and Investor Relations Contacts:**

**Perspective Therapeutics IR:**

Annie J. Cheng, CFA

ir@perspectivetherapeutics.com

**Russo Partners, LLC**

Nic Johnson

PerspectiveIR@russopr.com

------

## Exhibit 99.2

![img237154372_0.jpg](img237154372_0.jpg)

**Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting**

SEATTLE – June 21, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting taking place June 21-24, 2025 in New Orleans, Louisiana.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Lead author** | &nbsp;&nbsp;**Presentation Details** |
| &nbsp;&nbsp;Stephen Graves<br> &nbsp;&nbsp;[<sup>212</sup>Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2-positive tumors in the VMT-α-NET-T101 trial | &nbsp;&nbsp;**Abstract Number**: 251949<br>**Session Type:** Poster & Oral<br>**Poster Session Date:** June 21, 2025<br>**Oral session**: MTA07 Oncology: Clinical Diagnosis & Therapy Meet the Author Session, part 2 <br>**Oral Session Date**: June 23, 2025<br>**Oral Session Time:** 12:30 PM - 1:15 PM CDT |
| &nbsp;&nbsp;Lianbo Zhou<br> &nbsp;&nbsp;Preclinical evaluation and first-in-human case of [<sup>68</sup>Ga]Ga-PSV377, a novel cyclic radiopeptide targeting fibroblast activation protein, for positron emission tomography (PET) imaging of multiple cancers | &nbsp;&nbsp;**Abstract Number**: 251863<br>**Session Type:** Poster and Oral<br>**Poster Session Date:** June 21, 2025 <br>**Oral session**: MTA06 Oncology: Discovery & Translational Meet the Author Session<br>**Oral Session Date**: June 23, 2025<br>**Oral Session Time:** 10:30 AM - 11:15 AM CDT |

---

**[**<sup>212</sup>**Pb]VMT-α-NET**

This presentation reports on the dosimetry sub-study using [<sup>203</sup>Pb]VMT-α-NET as an imaging agent in the ongoing Phase 1/2a clinical trial of [<sup>212</sup>Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2) positive neuroendocrine tumors (NETs) who have not received a prior radiopharmaceutical therapy (RPT).

------

The findings of the study suggest that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•[<sup>212</sup>Pb]VMT-α-NET dosimetry using [<sup>203</sup>Pb]VMT-α-NET as an imaging surrogate is feasible and should be considered as a valuable adjunct to this trial's clinical data; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In general, this dosimetric approach can be a useful, complementary tool in the clinical development of <sup>212</sup>Pb-based therapies delivered with Perspective's proprietary chelator for <sup>212</sup>Pb and <sup>203</sup>Pb.

Safety data from the Company's Phase 1/2a clinical trial of [<sup>212</sup>Pb]VMT-α-NET demonstrated that [<sup>212</sup>Pb]VMT-α-NET was well-tolerated among all patients treated, many with long-term follow-up. Therefore, according to the presentation, the reported estimated cumulative absorbed doses of radiation to organs of interest in this analysis likely represent tolerable levels for [<sup>212</sup>Pb]VMT-α-NET. Dose escalation and further clinical observations are needed to establish the appropriate threshold levels of cumulative absorbed doses and appropriate Relative Biological Effectiveness (RBE) factor of <sup>212</sup>Pb delivered with Perspective's proprietary chelator.

**[**<sup>68</sup>**Ga]PSV377**

The presentation reports on the development and evaluation of a PET imaging agent [<sup>68</sup>Ga]PSV377, a <sup>212</sup>Pb radiopharmaceutical currently in a Phase I/IIa clinical trial for the treatment of tumors expressing fibroblast activation protein-α (FAP-α). According to the presentation, PSV377 exhibited strong affinity for hFAP, strong uptake and high tumor retention in a FAP-positive pre-clinical model (HT1080-hFAP). A first-in-human image in a patient with metastatic colorectal cancer showed higher uptake in tumor lesions as compared to <sup>18</sup>F-FDG.

**About [**<sup>212</sup>**Pb]VMT-α-NET**

Perspective designed [<sup>212</sup>Pb]VMT-α-NET to target and deliver <sup>212</sup>Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [<sup>212</sup>Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol.

------

**About PSV359**

PSV359 was designed to target and deliver <sup>212</sup>Pb to tumor sites expressing fibroblast activation protein-α, or FAP-α, associated with multiple highly prevalent solid tumors, with patients in need of additional treatment options. The targeting moiety may also be radiolabeled with <sup>203</sup>Pb or <sup>68</sup>Ga (known as PSV377) to detect FAP-α expression in individual patients. Preclinical imaging and therapy as well as human imaging results suggest Perspective's proprietary targeting ligand has improved levels of target engagement and uptake in tumors, as well as reduced retention in healthy tissues, which may result in a desirable therapeutic index. Perspective is conducting a multi-center, open-label, dose-finding and dose-expansion study (clinicaltrials.gov identifier NCT06710756) of [<sup>212</sup>Pb]PSV359 in patients with advanced solid tumors that express FAP-α as determined by imaging with [<sup>203</sup>Pb]PSV359, with first patient dosed in April 2025.

**About Perspective Therapeutics, Inc.**

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope <sup>212</sup>Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary <sup>212</sup>Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

------

**Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's preclinical and clinical development plans and the expected timing thereof; the expected timing for availability and release of additional data from the Company's clinical trials; the Company's anticipated timing and expectations regarding regulatory communications, requests, interactions, submissions, alignment, and approvals; the Company's belief that preclinical imaging and therapy as well as human imaging results suggest that PSV359 has improved levels of target engagement and uptake in tumors, as well as reduced tension in healthy issues; the ability of the Company's proprietary technology utilizing the alpha emitting isotope <sup>212</sup>Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary <sup>212</sup>Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

------

**Media and Investor Relations Contacts:**

**Perspective Therapeutics IR:**

Annie J. Cheng, CFA

ir@perspectivetherapeutics.com

**Russo Partners, LLC**

Nic Johnson

PerspectiveIR@russopr.com

------

## Exhibit 99.3

![Slide 1](catx-ex99_3s1.jpg)

[212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2 positive tumors in the VMT-α-NET-T101 trial Stephen A. Graves1, Thorvardur R. Halfdanarson2, Richard L. Wahl3, Lowell Anthony4, Lilja B. Solnes5, Sam H. Mehr6, Ian R. Marsh7, Lucia Baratto7, Stephen M. Keefe7, Markus Puhlmann7, Vikas Prasad3 1University of Iowa, 2Mayo Clinic, 3Washington University, 4University of Kentucky, 5Johns Hopkins, 6Nebraska Cancer Specialists, 7Perspective Therapeutics [212Pb]Pb-VMT-α-NET is a novel alpha-emitting radiopharmaceutical therapy (RPT) developed for the treatment of somatostatin receptor subtype 2 expressing (SSTR2) tumors. VMT-α-NET-T101 (NCT05636618) is a multi-center phase I/IIa trial of [212Pb]Pb-VMT-α-NET in PRRT-naïve patients with unresectable or metastatic SSTR2+ neuroendocrine tumors. As part of this investigation, a subset of patients were enrolled in a dosimetry sub-study utilizing pre-treatment SPECT imaging of [203Pb]Pb-VMT-α-NET. Here we present preliminary dosimetry analysis for [212Pb]Pb-VMT-α-NET based on theranostic imaging studies of [203Pb]Pb-VMT-α-NET. Background Study Design: VMT-α-NET-T101 VMT-α-NET Dosimetry The theranostic pairing of 203Pb and 212Pb provides a valuable tool for imaging, dosimetry, and treatment. [212Pb]VMT-α-NET dosimetry using [203Pb]VMT-α-NET as a theranostic imaging surrogate is feasible and should be considered as a valuable adjunct to this trial's clinical data. The most appropriate RBE weighting may be radionuclide- and agent-specific. RBE=5 may not be applicable for every targeted-alpha particle RPT. Taken together, these clinical safety data and dosimetry analyses suggest that the reported estimated cumulative absorbed doses of radiation to organs of interest likely represent tolerable levels for [212Pb]VMT-α-NET. Ultimately, clinical safety data will drive and set these limits. Conclusions Patient eligibility was assessed based on approved DOTATATE PET imaging. A pre-therapy multi-timepoint imaging study using 6.0 mCi (222 MBq) of [203Pb]Pb-VMT-α-NET was acquired for dosimetry analysis. SPECT/CT images of [203Pb]Pb-VMT-α-NET were acquired at 1, 4, and 24 h following administration. Blood & urine samples were collected through 24 h post administration. The mean time between SPECT imaging and therapy was 9 ± 5 days. Standard amino acid co-administration was used for both [203Pb]Pb-VMT-α-NET and [212Pb]Pb-VMT-α-NET. Dosimetry sub-study patients (n = 6) were enrolled across 3 clinical sites. Dosimetry Sub-Study Time-Activity Curves Modeling Redistribution of 212Bi Quantitative SPECT Imaging of 203Pb Partial Volume Correction Safety & Efficacy Profile Pharmacokinetic model for bismuth in the human body. Reproduced from ICRP Report 137 6. Elementally Matched Theranostic Pair 212Bi Bismuth 60.6 m 208Tl Thallium 3.1 m 212Po Polonium 0.3 µs 208Pb Lead Stable 212Pb Lead 10.6 h β- 203Tl Thallium Stable 203Pb Lead 51.9 h 0.57 MeV β- (64%) 2.3 MeV α (36%) 6.1 MeV β- 1.8 MeV α 8.8 MeV ε γ 279 keV Creatinine (mg/dL) Study Week 0 24 48 64 8 16 32 72 56 40 5 4 3 2 0 1 Treatment-emergent adverse events (all patients treated, n = 42). Blood creatinine during follow-up for all patients treated (n = 42). Data cutoff 2025-04-30. Clinical data from this trial has been summarized as of 2025-04-30 Safety data are reported for all patients treated, n = 42 Efficacy data reported for patients enrolled for DLT-observation, n = 9 Safety data demonstrate a tolerable profile No DLTs observed among patients treated with [212Pb]VMT-α-NET No grade ≥ 4 AEs were reported No treatment-related discontinuations occurred No serious renal complications or myelosuppression was reported No dysphagia was reported Clinical activity was observed 7 of 9 DLT-observation patients were without progression after more than 1y of follow-up Investigator-assessed RECIST v1.1 objective responses were observed among 4 of 7 cohort two DLT-observation patients (three confirmed) [212Pb]Pb-VMT-α-NET Neuroendocrine tumors are heterogenous. >80% overexpress somatostatin receptor 2 (SSTR2). Despite the availability of [177Lu]Lu-DOTATATE, there remains a high unmet medical need for novel therapies. VMT-α-NET is a modified SSTR2 binding peptide with proprietary chelation technology for 203Pb, 212Pb, & 212Bi. PSC – A Proprietary Lead-Specific Chelator1 Designed specifically for Pb isotopes. Optimized for rapid renal clearance with neutralized formal charge. Improved radiolabeling, receptor binding, & internalization. Enhanced retention of 212Bi, reducing off-target toxicity. 212Pb2+ NET 0 PSC Molecular Weight: 1789.83 212Pb2+ DOTA 212Pb2+ NET 2+ NET 2- TCMC Generic Chelators Charged molecules can be more often reabsorbed through the kidneys.2 212Bi leaks from these chelators at up to 36%.3 Dose-finding phase Expansion phase Recommended Phase 2 Dose (RP2D) Expansion Cohort [212Pb]Pb-VMT--NET RP2D mCi x 4 Recruited Cohort 2 [212Pb]Pb-VMT--NET n = 7 / 5 mCi x 4 Cohort 3 [212Pb]Pb-VMT--NET n = 3 – 8 / 7.5 mCi x 4 Recruitment Complete Cohort 1 [212Pb]Pb-VMT--NET n = 2 / 2.5 mCi x 4 Cohort 4 [212Pb]Pb-VMT--NET n = 3 – 8 / 10 mCi x 4 Pre-agreed FDA interaction before dosing next cohort Expansion into non-NET indications (e.g., SCLC) also possible Intermediate doses or de-escalation possible for Cohort 2 - 4 Added slots: Total of up to 47 (Recruitment ongoing) Dose-finding Population Key Study Features Study Endpoints Advanced/Unresectable or metastatic NETs Progressive disease on prior therapy PRRT naive FDA approved SSTR2 PET/CT avid disease Bayesian mTPI-2 design based on iterative toxicity probability monitoring Dosimetry to be assessed during screening period for cohorts 1 & 2 using [203Pb]Pb-VMT--NET Primary: to measure incidence of DLTs following a single administration of [212Pb] Pb-VMT--NET in order to determine the MTD and/or MFD, and RP2D Secondary / exploratory ORR, DOR, PFS, OS by RECIST v1.1 Using dosimetry, estimate selected organ and whole body absorbed radiation doses for [212Pb]Pb-VMT--NET Trial Parameters (NCT05636618) 79 mm 200 mm 200 mm 250 ml Nalgene bottle References Diagnostic Therapeutic Li M, Baumhover NJ, Liu D, et al. Pharmaceutics. 2023. Paquet F, Bailey MR, Leggett RW, et al. ICRP Publication 137. Ann ICRP. 2017. ICRP Publication 103. Ann ICRP. 2007 Bolch WE, Eckerman KF, Sgouros G, et al. MIRD Pamphlet 21. J Nucl Med. 2009. [203Pb]Pb-VMT-α-NET [212Pb]Pb-VMT-α-NET [68Ga]Ga- / [64Cu]Cu-DOTATATE PET/CT Imaging SPECT/CT Imaging (7-14 d) (<6 months) (8 wks) (8 wks) (8 wks) 203Pb SPECT images were acquired using a triple energy window centered on the 279 keV photopeak (20%) with upper and lower scatter windows (10%). SPECT reconstruction was performed using CT-based attenuation correction and a window-based scatter correction. SPECT sensitivity factors (cps/MBq) were derived from phantom calibration studies4. A 100 ml reference standard was included in each patient scan for quality assurance. Phantom-based SPECT Calibration 1 h 4 h 24 h 4 h [203Pb]Pb-VMT-α-NET Cylindrical solid water phantom (Graves Phantom) used for quantitative 203Pb SPECT calibration studies. The bottle ROI is morphologically expanded by 10 mm in all dimensions to capture activity spill out when determining a sensitivity factor. SPECT/CT imaging of [203Pb]Pb-VMT-α-NET in a representative patient (103-105). Maximum intensity projections (MIPs) of SPECT images at each timepoint (above) alongside transaxial and coronal slices of the liver at 4 h (below), showing tumor-specific uptake and retention. Regions of interest were delineated for the kidneys, liver, spleen, whole body, and tumors based on anatomic and functional imaging. Time-activity curves (TACs) were generated for [212Pb]Pb-VMT-α-NET, accounting for the differences in physical decay between 203Pb (t1/2 = 51.9 h) and 212Pb (t1/2 = 10.6 hours). TACs were fit to either mono-exponential or bi-exponential functions, depending on goodness of fit. Mono-exponential Bi-exponential Time activity curves in units of percent injected activity of [212Pb]Pb-VMT-α-NET for select normal tissues and lesions in a representative patient (103-101). Dosimetry analysis for [212Pb]Pb-VMT-α-NET was performed using the MIRD methodology with OLINDA v2.2.3 and is based on multi-timepoint SPECT imaging of [203Pb]Pb-VMT-α-NET. Results are reported both in terms of physical abs. dose and RBE-weighted dose (RBE = 5). Dose calculations for [212Pb]Pb-VMT-α-NET account for all daughters in the decay chain (weighted by branching ratio), partial volume effects, and redistribution of progeny 212Bi. Bone marrow dosimetry was estimated using decay corrected blood activity concentration measurements from [203Pb]Pb-VMT-α-NET. With a half-life of 61 minutes, the redistribution of progeny 212Bi following 212Pb beta decay can describe the fate of all 212Pb daughters. Redistribution of progeny 212Bi was modeled using a whole-body pharmacokinetic model based on transfer coefficients published in ICRP 137. For [212Pb]Pb-VMT-α-NET, utilizing PSC, the release fraction (RF) of 212Bi is taken to be 5%.5 Relative Biological Effectiveness RBE is defined as the ratio of a dose of low-LET reference radiation (e.g. x-rays) to a dose of high-LET radiation that produce the same biological effect.7 Experimentally reported RBE values range from 1 to 8 for cell killing, in vivo, and differ based on the biological endpoint, reference radiation, and alpha particle energy.8 In the absence of any clinical data to support a specific RBE value for [212Pb]Pb-VMT-α-NET, it is generally conventional to conservatively assume an RBE weighting factor of 5 for all alpha-particle dose contributions. Normal Tissues %/RF PSC (RF = 5%) DOTA (RF = 36%) Kidneys +0.79% +3.94% +28.35% Spleen -0.18% -0.91% -6.55% Liver +0.46% +2.28% +16.44% Red Marrow -0.50% -2.48% -17.82% Summary of the impact of 212Bi redistribution on the TIAC for select organs. The limited spatial resolution of SPECT causes partial volume effects that result in underestimation of activity in ROIs, particularly for smaller ROIs. A dual contouring approach was used to correct for partial volume effects in the kidney and lesion ROI analysis. Contours were first delineated on the CT images to determine the volume of the ROI. A second set of ROIs was then generated to capture the apparent activity of the ROI in the 4 h SPECT image, accounting for spill out activity and organ displacement between SPECT and CT acquisitions. For the kidney, functional ROIs were generated by morphologically expanding the anatomic volume by 5 mm in all dimensions. The average recovery coefficients were 0.72 ± 0.05 for the kidneys and 0.44 ± 0.12 for the lesions. The study team deeply thanks patients and their families for participating in this clinical trial. This study is a multicenter clinical trial with enrollment from 11 clinical trial sites, and many thanks are extended to investigators and site personnel for their incredible partnership in this work. Acknowledgements ROI Dose Coeff. (Gy/mCi) mean SD min max Kidneys 0.40 0.10 0.23 0.48 Spleen 0.22 0.12 0.11 0.43 Liver 0.11 0.04 0.07 0.16 Red Marrow 0.019 0.006 0.012 0.026 Lesions 1.08 0.61 0.36 2.83 Dose coefficient for [212Pb]Pb-VMT-α-NET without RBE-weighting and no redistribution of progeny 212Bi. ROI Dose Coeff., (Gy/mCi, RBE = 5) mean SD min max Kidneys 1.88 0.46 1.07 2.29 Spleen 0.99 0.56 0.50 1.92 Liver 0.52 0.18 0.32 0.73 Red Marrow 0.084 0.047 0.040 0.170 Lesions 5.00 2.82 1.68 13.07 RBE-weighted dose coefficient for [212Pb]Pb-VMT-α-NET assuming RBE=5 and accounting for 212Bi redistribution. ROI Cumulative Abs. Dose (Gy) 4 x 2.5 mCi 4 x 5.0 mCi mean SD mean SD Kidneys 4.0 1.0 8.0 1.9 Spleen 2.2 1.2 4.4 2.5 Liver 1.1 0.4 2.3 0.8 Red Marrow 0.19 0.06 0.38 0.1 Tumors 10.8 6.1 21.6 12.2 Cumulative absorbed dose for a full course of treatment with [212Pb]Pb-VMT-α-NET, without RBE weighting and no redistribution of 212Bi. Cumulative RBE-weighted dose for a full course of treatment with [212Pb]Pb-VMT-α-NET, assuming RBE=5 and accounting for redistribution of 212Bi. ROI Cumulative Abs. Dose (Gy, RBE=5) 4 x 2.5 mCi 4 x 5.0 mCi mean SD mean SD Kidneys 18.8 4.6 37.7 9.2 Spleen 9.9 5.6 19.7 11.2 Liver 5.2 1.8 10.5 3.5 Red Marrow 0.8 0.47 1.7 0.9 Tumors 50.0 28.2 100.0 56.5 PSC Patent Published, US12128115B2 Vegt E, de Jong M, Wetzels JF, et al. J Nucl Med. 2010. Mirzadeh S, Kumar K, Gansow OA. Radiochimica Acta. 1993. Graves S, Merrick M, Tiwari A, Sunderland J. J Nucl Med. 2021. Spider plot of tumor change over time by patient (all patients enrolled for DLT-observation, n = 9). Data cutoff 2025-04-30. Cohort 1 [212Pb]VMT--NET 2.5mCi Cohort 2 [212Pb]VMT--NET 5.0mCi Percent change in sum of diameters from baseline Preferred Term Grade 1-2 Grade 3 Total Cohort 1, 2.5 mCi n = 2, (n) Cohort 2, 5 mCi n = 40, (n) Cohort 1, 2.5 mCi n = 2, (n) Cohort 2, 5 mCi n = 40, (n) n = 42 [n (%)] Summary of TEAEs per patient 2 37 – 10 39 (93) Fatigue 2 23 – – 25 (60) Alopecia 2 20 – – 22 (52) Nausea 1 17 – – 18 (43) Diarrhea 2 9 – 3 14 (33) Anemia 2 9 – – 11 (26) Lymphocyte count decreased 1 7 – 3 11 (26) Abdominal pain 1 9 – – 10 (24) AST Increased 1 6 – – 7 (17) Blood creatinine increased – 7 – – 7 (17) ALT increased – 6 – – 6 (14) Hyperglycemia – 6 – – 6 (14) Hypocalcemia – 6 – – 6 (14) Back pain – 5 – – 5 (12) Headache 1 4 – – 5 (12) Hypertension – 3 – 2 5 (12) Vomiting – 4 – 1 5 (12) Hypokalemia – 1 – 1 2 (5) Presyncope – 1 – 1 2 (5) Cardiac failure – – – 1 1 (2) Syncope – – – 1 1 (2) The longer half-life of Pb-203 (51.9 h) allows for improved characterization of the biodistribution of 212Pb (10.6 h) at late timepoints. Representative example of the dual contouring approach for the kidney with anatomic (blue) and functional (green) ROIs.

## Exhibit 99.4

![Slide 1](catx-ex99_4s1.jpg)

Corporate Presentation

------

![Slide 2](catx-ex99_4s2.jpg)

------

![Slide 3](catx-ex99_4s3.jpg)

Developing the Next Generation of Targeted Therapies

------

![Slide 4](catx-ex99_4s4.jpg)

Higher Potency Payloads with Cancer-Specific Targeting

------

![Slide 5](catx-ex99_4s5.jpg)

------

![Slide 6](catx-ex99_4s6.jpg)

Radiopharmaceutical Therapy Poised to Revolutionize Oncology TreatmentPerspective's pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

------

![Slide 7](catx-ex99_4s7.jpg)

------

![Slide 8](catx-ex99_4s8.jpg)

Perspective's Innovative Platform

------

![Slide 9](catx-ex99_4s9.jpg)

Perspective's Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window

------

![Slide 10](catx-ex99_4s10.jpg)

Perspective's Proprietary Chelator Has Been Optimized for Lead-Based RPTs

------

![Slide 11](catx-ex99_4s11.jpg)

------

![Slide 12](catx-ex99_4s12.jpg)

------

![Slide 13](catx-ex99_4s13.jpg)

Proposed Mechanism of Action for 212Pb

------

![Slide 14](catx-ex99_4s14.jpg)

Rationale for Synergy with Immune Checkpoint Inhibitors

------

![Slide 15](catx-ex99_4s15.jpg)

------

![Slide 16](catx-ex99_4s16.jpg)

Supply Chain and Manufacturing Infrastructure

------

![Slide 17](catx-ex99_4s17.jpg)

On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products

------

![Slide 18](catx-ex99_4s18.jpg)

------

![Slide 19](catx-ex99_4s19.jpg)

Neuroendocrine Tumors: VMT-⍺-NET

------

![Slide 20](catx-ex99_4s20.jpg)

------

![Slide 21](catx-ex99_4s21.jpg)

------

![Slide 22](catx-ex99_4s22.jpg)

------

![Slide 23](catx-ex99_4s23.jpg)

Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors

------

![Slide 24](catx-ex99_4s24.jpg)

Anti-Tumor Activity

------

![Slide 25](catx-ex99_4s25.jpg)

Signal of Sustained Anti-Tumor Activity

------

![Slide 26](catx-ex99_4s26.jpg)

[212Pb]VMT-α-NET Was Well Tolerated

------

![Slide 27](catx-ex99_4s27.jpg)

Mild and Generally Transient Blood Creatinine Increase

------

![Slide 28](catx-ex99_4s28.jpg)

------

![Slide 29](catx-ex99_4s29.jpg)

Patient (103-105) with Confirmed PR After [212Pb]VMT-α-NET

------

![Slide 30](catx-ex99_4s30.jpg)

Melanoma Program: VMT01/02

------

![Slide 31](catx-ex99_4s31.jpg)

------

![Slide 32](catx-ex99_4s32.jpg)

------

![Slide 33](catx-ex99_4s33.jpg)

------

![Slide 34](catx-ex99_4s34.jpg)

------

![Slide 35](catx-ex99_4s35.jpg)

Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma

------

![Slide 36](catx-ex99_4s36.jpg)

------

![Slide 37](catx-ex99_4s37.jpg)

Treatment Emergent Adverse Events (all grades, occurring in ≥ 2 patients)

------

![Slide 38](catx-ex99_4s38.jpg)

------

![Slide 39](catx-ex99_4s39.jpg)

------

![Slide 40](catx-ex99_4s40.jpg)

------

![Slide 41](catx-ex99_4s41.jpg)

------

![Slide 42](catx-ex99_4s42.jpg)

------

![Slide 43](catx-ex99_4s43.jpg)

PSV359 is Active Against FAP-α Expression on Tumor and on Stroma

------

![Slide 44](catx-ex99_4s44.jpg)

------

![Slide 45](catx-ex99_4s45.jpg)

------

![Slide 46](catx-ex99_4s46.jpg)

Trial Design: [212Pb]PSV359 Phase 1/2a Trial

------

![Slide 47](catx-ex99_4s47.jpg)

------

![Slide 48](catx-ex99_4s48.jpg)

General Corporate Information

------

![Slide 49](catx-ex99_4s49.jpg)

------

![Slide 50](catx-ex99_4s50.jpg)

------

![Slide 51](catx-ex99_4s51.jpg)

------

![Slide 52](catx-ex99_4s52.jpg)

------

![Slide 53](catx-ex99_4s53.jpg)

Abbreviations

------

![Slide 54](catx-ex99_4s54.jpg)

APPENDIX

------

![Slide 55](catx-ex99_4s55.jpg)

------

![Slide 56](catx-ex99_4s56.jpg)

NETs Trials

------

![Slide 57](catx-ex99_4s57.jpg)

Refractory Metastatic Melanoma Trials

------

![Slide 58](catx-ex99_4s58.jpg)

------

![Slide 59](catx-ex99_4s59.jpg)

------

![Slide 60](catx-ex99_4s60.jpg)

------

![Slide 61](catx-ex99_4s61.jpg)

------

![Slide 62](catx-ex99_4s62.jpg)

------

![Slide 63](catx-ex99_4s63.jpg)

Perspective's Pre-Targeting Platform